清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

舒尼替尼 医学 肾细胞癌 内科学 危险系数 中止 胃肠病学 临床终点 不利影响 对数秩检验 替西罗莫司 无进展生存期 肿瘤科 泌尿科 比例危险模型 随机对照试验 置信区间 总体生存率 细胞凋亡 化学 mTOR抑制剂的发现与发展 蛋白激酶B 生物化学
作者
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Négrier,Cezary Szczylik,Роберто Пили,Georg A. Bjarnason,Xavier García del Muro,Jeffrey A. Sosman,E Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (11): 1965-1971 被引量:159
标识
DOI:10.1200/jco.22.02623
摘要

Purpose A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. Patients and Methods Seven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-α 9 MU subcutaneously thrice weekly. Overall survival was compared by two-sided log-rank and Wilcoxon tests. Progression-free survival, response, and safety end points were assessed with updated follow-up. Results Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 months, respectively; hazard ratio [HR] = 0.821; 95% CI, 0.673 to 1.001; P = .051) per the primary analysis of unstratified log-rank test ( P = .013 per unstratified Wilcoxon test). By stratified log-rank test, the HR was 0.818 (95% CI, 0.669 to 0.999; P = .049). Within the IFN-α group, 33% of patients received sunitinib, and 32% received other vascular endothelial growth factor–signaling inhibitors after discontinuation from the trial. Median progression-free survival was 11 months for sunitinib compared with 5 months for IFN-α ( P < .001). Objective response rate was 47% for sunitinib compared with 12% for IFN-α ( P < .001). The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%). Conclusion Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sh1ro发布了新的文献求助10
5秒前
nojego完成签到,获得积分10
14秒前
脑洞疼应助科研通管家采纳,获得10
29秒前
顾矜应助科研通管家采纳,获得10
29秒前
wjx完成签到 ,获得积分10
30秒前
John完成签到,获得积分10
41秒前
顾矜应助ceeray23采纳,获得20
52秒前
1分钟前
Able完成签到,获得积分10
1分钟前
我是笨蛋完成签到 ,获得积分10
1分钟前
ceeray23发布了新的文献求助20
1分钟前
Owen应助董可以采纳,获得10
1分钟前
酷酷妙梦完成签到,获得积分10
1分钟前
科研通AI2S应助彦嘉采纳,获得10
2分钟前
小二郎应助科研通管家采纳,获得10
2分钟前
hhh2018687完成签到,获得积分10
2分钟前
科研通AI2S应助ceeray23采纳,获得20
2分钟前
忘忧Aquarius完成签到,获得积分10
2分钟前
wujiwuhui完成签到 ,获得积分10
2分钟前
Lny发布了新的文献求助30
3分钟前
sh1ro完成签到,获得积分10
3分钟前
luang应助ceeray23采纳,获得40
3分钟前
3分钟前
ww完成签到,获得积分10
4分钟前
斯文败类应助ceeray23采纳,获得20
4分钟前
机智秋莲发布了新的文献求助20
4分钟前
ChatGPT完成签到,获得积分10
4分钟前
所所应助科研通管家采纳,获得10
4分钟前
4分钟前
4分钟前
ceeray23发布了新的文献求助20
4分钟前
海阔天空完成签到 ,获得积分10
5分钟前
zys发布了新的文献求助10
5分钟前
ffdhdh应助LYZSh采纳,获得10
5分钟前
5分钟前
机智秋莲完成签到,获得积分20
6分钟前
欣欣子完成签到 ,获得积分10
6分钟前
apt完成签到 ,获得积分10
6分钟前
科研通AI2S应助科研通管家采纳,获得10
6分钟前
7分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990543
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271057
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234